
|Videos|October 26, 2016
Results of a Trial Comparing Cabozantinib and Sunitinib in mRCC
Author(s)Toni Choueiri, MD
Toni Choueiri, MD, discusses the results of the ALLIANCE A031203 trial comparing cabozantinib and sunitinib in metastatic renal cell carcinoma (mRCC).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















